SCHEMBL15041567

SCHEMBL15041567

CN1CC(n2c(=O)c(C#N)cc3cnc(Nc4ccc(C5=CCNCC5)cc4)nc32)Cc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 16/20 0.51
CCND1 P24385 13/20 0.51
CCNA2 P20248 12/20 0.51
CDK2 P24941 12/20 0.51
FGFR1 P11362 9/20 0.51
CDK6 Q00534 4/20 0.51
NUAK1 O60285 3/20 0.51
PIK3CD O00329 1/20 0.51
PRKAB2 O43741 1/20 0.51
CCNT1 O60563 1/20 0.51
ABL1 P00519 1/20 0.51
FYN P06241 1/20 0.51
CDK1 P06493 1/20 0.51
CSF1R P07333 1/20 0.51
RET P07949 1/20 0.51
PDGFRB P09619 1/20 0.51
CCNB1 P14635 1/20 0.51
CCNE1 P24864 1/20 0.51
MARK3 P27448 1/20 0.51
FLT3 P36888 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035381 0.93 CDK4 (0.43) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15041620 0.86 CDK4 (0.49) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15035250 0.86 TNK2 (0.43) CDK4FGFR1CDK6ABL1PDGFRB
SCHEMBL15035589 0.79 CDK4 (0.43) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15041298 0.77 CDK4 (0.43) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL22171250 0.76 CDK4 (0.70) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15035520 0.74 CDK4 (0.42) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL28572987 0.74 CDK4 (0.63) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15041821 0.72 CDK4 (0.47) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15035257 0.72 CDK4 (0.42) CDK4CCND1CCNA2CDK2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 CDK4 404/4885CCND1 2153/4885CCNA2 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.